Lipoxin A(4) levels in asthma: relation with disease severity and aspirin sensitivity

ÇELİK G. E., Erkekol F. O., Misirligil Z., Melli M.

CLINICAL AND EXPERIMENTAL ALLERGY, vol.37, no.10, pp.1494-1501, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 10
  • Publication Date: 2007
  • Doi Number: 10.1111/j.1365-2222.2007.02806.x
  • Journal Name: CLINICAL AND EXPERIMENTAL ALLERGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1494-1501
  • Keywords: aspirin, aspirin-exacerbated respiratory disease, asthma, 15-epi-lipoxin A(4) inflammation, lipoxin A(4), severity, PERIPHERAL-BLOOD LEUKOCYTES, NASAL POLYPS, CYSTEINYL-LEUKOTRIENES, ANTI-INFLAMMATION, PROSTAGLANDIN E-2, LIPID MEDIATORS, CYCLOOXYGENASE, EXPRESSION, TOLERANT, HYPERSENSITIVITY
  • Ankara University Affiliated: Yes

Abstract

Background Lipoxin (LX) A(4), an endogenous anti-inflammatory eicosanoid, has been found to be low in patients with severe asthma. However, few studies also suggested more diminished LX A(4) levels in aspirin-exacerbated respiratory disease (AERD) when compared with aspirin-tolerant asthma (ATA). It is, therefore, currently not clear whether the asthma severity or the presence of AERD has a primary role in the disturbed LX metabolism.